Cargando…
NIAID resources for developing new therapies for severe viral infections
Severe viral infections, including hemorrhagic fever and encephalitis, occur throughout the world, but are most prevalent in developing areas that are most vulnerable to infectious diseases. Some of these can also infect related species as illustrated by the threatened extinction of gorillas by Ebol...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132394/ https://www.ncbi.nlm.nih.gov/pubmed/18061283 http://dx.doi.org/10.1016/j.antiviral.2007.10.006 |
_version_ | 1783517427476201472 |
---|---|
author | Greenstone, Heather Spinelli, Beth Tseng, Christopher Peacock, Susan Taylor, Katherine Laughlin, Catherine |
author_facet | Greenstone, Heather Spinelli, Beth Tseng, Christopher Peacock, Susan Taylor, Katherine Laughlin, Catherine |
author_sort | Greenstone, Heather |
collection | PubMed |
description | Severe viral infections, including hemorrhagic fever and encephalitis, occur throughout the world, but are most prevalent in developing areas that are most vulnerable to infectious diseases. Some of these can also infect related species as illustrated by the threatened extinction of gorillas by Ebola infection in west and central Africa. There are no safe and effective treatments available for these serious infections. In addition to the logistical difficulties inherent in developing a drug for infections that are sporadic and occur mainly in the third world, there is the overwhelming barrier of no hope for return on investment to encourage the pharmaceutical industry to address these unmet medical needs. Therefore, the National Institute of Allergy and infectious Disease (NIAID) has developed and supported a variety of programs and resources to provide assistance and lower the barrier for those who undertake these difficult challenges. The primary programs relevant to the development of therapies for severe viral infections are described and three case studies illustrate how they have been used. In addition, contact information for accessing these resources is supplied. |
format | Online Article Text |
id | pubmed-7132394 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-71323942020-04-08 NIAID resources for developing new therapies for severe viral infections Greenstone, Heather Spinelli, Beth Tseng, Christopher Peacock, Susan Taylor, Katherine Laughlin, Catherine Antiviral Res Article Severe viral infections, including hemorrhagic fever and encephalitis, occur throughout the world, but are most prevalent in developing areas that are most vulnerable to infectious diseases. Some of these can also infect related species as illustrated by the threatened extinction of gorillas by Ebola infection in west and central Africa. There are no safe and effective treatments available for these serious infections. In addition to the logistical difficulties inherent in developing a drug for infections that are sporadic and occur mainly in the third world, there is the overwhelming barrier of no hope for return on investment to encourage the pharmaceutical industry to address these unmet medical needs. Therefore, the National Institute of Allergy and infectious Disease (NIAID) has developed and supported a variety of programs and resources to provide assistance and lower the barrier for those who undertake these difficult challenges. The primary programs relevant to the development of therapies for severe viral infections are described and three case studies illustrate how they have been used. In addition, contact information for accessing these resources is supplied. Elsevier 2008-04 2007-11-09 /pmc/articles/PMC7132394/ /pubmed/18061283 http://dx.doi.org/10.1016/j.antiviral.2007.10.006 Text en Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Greenstone, Heather Spinelli, Beth Tseng, Christopher Peacock, Susan Taylor, Katherine Laughlin, Catherine NIAID resources for developing new therapies for severe viral infections |
title | NIAID resources for developing new therapies for severe viral infections |
title_full | NIAID resources for developing new therapies for severe viral infections |
title_fullStr | NIAID resources for developing new therapies for severe viral infections |
title_full_unstemmed | NIAID resources for developing new therapies for severe viral infections |
title_short | NIAID resources for developing new therapies for severe viral infections |
title_sort | niaid resources for developing new therapies for severe viral infections |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132394/ https://www.ncbi.nlm.nih.gov/pubmed/18061283 http://dx.doi.org/10.1016/j.antiviral.2007.10.006 |
work_keys_str_mv | AT greenstoneheather niaidresourcesfordevelopingnewtherapiesforsevereviralinfections AT spinellibeth niaidresourcesfordevelopingnewtherapiesforsevereviralinfections AT tsengchristopher niaidresourcesfordevelopingnewtherapiesforsevereviralinfections AT peacocksusan niaidresourcesfordevelopingnewtherapiesforsevereviralinfections AT taylorkatherine niaidresourcesfordevelopingnewtherapiesforsevereviralinfections AT laughlincatherine niaidresourcesfordevelopingnewtherapiesforsevereviralinfections |